Background: Continuous renal replacement therapy (CRRT) technique may affect circuit lifespan. A shorter circuit life may reduce CRRT efficacy and increase costs. Methods: In a before-and-after study, we compared circuit median survival time during continuous venovenous hemofiltration (CVVH) versus continuous venovenous hemodialysis (-CVVHD). We performed log-rank mixed effects univariate analysis and Cox mixed effect regression modeling to define predictors of circuit lifespan. Results: We compared 197 -CVVHD and 97 CVVH circuits in 39 patients. There was no overall difference in circuit lifespan. When no anticoagulation was used, median circuit survival time was shorter for CVVH circuits (5 h, 95% CI 3–7 vs. 10 h, 95% CI 8–13, p < 0.01). Moreover, CVVHD, lower platelets levels, and longer activated partial thromboplastin time independently predicted longer circuit median survival time. Conclusions: CVVHD is associated with longer circuit median survival time than CVVH when no anticoagulation is used and is an independent predictor of circuit survival.

Keywords:
Continuous venovenous hemodialysis, Continuous renal replacement therapy, Circuit survival, Clotting, Anticoagulation, Acute kidney injury
1.
Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, et al.; Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators. Acute renal failure in critically ill patients: a multinational, multicenter study.
JAMA
. 2005 Aug;294(7):813–8.
2.
Hoste EA, Bagshaw SM, Bellomo R, Cely CM, Colman R, Cruz DN, et al. Epidemiology of acute kidney injury in critically ill ­patients: the multinational AKI-EPI study.
Intensive Care Med
. 2015 Aug;41(8):1411–23.
3.
Vaara ST, Bellomo R. Extra-renal indications for continuous renal replacement therapy.
Contrib Nephrol
. 2018;194:90–8.
4.
Uchino S, Fealy N, Baldwin I, Morimatsu H, Bellomo R. Continuous is not continuous: the incidence and impact of circuit “down-time” on uraemic control during continuous veno-venous haemofiltration.
Intensive Care Med
. 2003 Apr;29(4):575–8.
5.
Joannidis M, Oudemans-van Straaten HM. Clinical review: patency of the circuit in continuous renal replacement therapy.
Crit Care
. 2007;11(4):218.
6.
Chua HR, Baldwin I, Bailey M, Subramaniam A, Bellomo R. Circuit lifespan during continuous renal replacement therapy for combined liver and kidney failure.
J Crit Care
. 2012 Dec;27(6):744.e7–15.
7.
Agarwal B, Shaw S, Shankar Hari M, Burroughs AK, Davenport A. Continuous renal replacement therapy (CRRT) in patients with liver disease: is circuit life different?
J Hepatol
. 2009 Sep;51(3):504–9.
8.
Brain M, Winson E, Roodenburg O, McNeil J. Non anti-coagulant factors associated with filter life in continuous renal replacement therapy (CRRT): a systematic review and meta-analysis.
BMC Nephrol
. 2017 Feb;18(1):69.
9.
Klingel R, Schaefer M, Schwarting A, Himmelsbach F, Altes U, Uhlenbusch-Körwer I, et al. Comparative analysis of procoagulatory activity of haemodialysis, haemofiltration and haemodiafiltration with a polysulfone membrane (APS) and with different modes of enoxaparin anticoagulation.
Nephrol Dial Transplant
. 2004 Jan;19(1):164–70.
10.
Monchi M, Berghmans D, Ledoux D, Canivet JL, Dubois B, Damas P. Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study.
Intensive Care Med
. 2004 Feb;30(2):260–5.
11.
Liu C, Mao Z, Kang H, Hu J, Zhou F. Regional citrate versus heparin anticoagulation for continuous renal replacement therapy in critically ill patients: a meta-analysis with trial sequential analysis of randomized controlled trials.
Crit Care
. 2016 May;20(1):144.
12.
Tovey L, Dickie H, Gangi S, Terblanche M, McKenzie C, Beale R, et al. Beyond the randomized clinical trial: citrate for continuous renal replacement therapy in clinical practice.
Nephron Clin Pract
. 2013;124(1-2):119–23.
13.
Gattas D, Rajbhandari D, Bradford C, Buhr H, Lo S, Bellomo R. A randomized controlled trial of regional citrate versus regional heparin anticoagulation for continuous renal replacement therapy in critically ill adults.
Crit Care Med
. 2015 Aug;43(8):1622–9.
14.
Kroll MH, Hellums JD, McIntire LV, Schafer AI, Moake JL. Platelets and shear stress.
Blood
. 1996 Sep;88(5):1525–41.
15.
Ricci Z, Ronco C, Bachetoni A, D’amico G, Rossi S, Alessandri E, et al. Solute removal during continuous renal replacement therapy in critically ill patients: convection versus diffusion.
Crit Care
. 2006;10(2):R67.
16.
Wald R, Friedrich JO, Bagshaw SM, Burns KE, Garg AX, Hladunewich MA, et al. Optimal Mode of clearance in critically ill patients with Acute Kidney Injury (OMAKI)–a pilot randomized controlled trial of hemofiltration versus hemodialysis: a Canadian Critical Care Trials Group project.
Crit Care
. 2012 Oct;16(5):R205.
17.
Dunn WJ, Sriram S. Filter lifespan in critically ill adults receiving continuous renal replacement therapy: the effect of patient and treatment-related variables.
Crit Care Resusc
. 2014 Sep;16(3):225–31.
18.
Fealy N, Aitken L, du Toit E, Lo S, Baldwin I. Faster blood flow rate does not improve circuit life in continuous renal replacement therapy: a randomized controlled trial.
Crit Care Med
. 2017 Oct;45(10):e1018–25.
19.
Kim I, Fealy N, Baldwin I, Bellomo R. A comparison of the NiagaraTM and Dolphin® catheters for continuous renal replacement therapy.
Int J Artif Organs
. 2011 Nov;34(11):1061–6.
20.
Bai M, Zhou M, He L, Ma F, Li Y, Yu Y, et al. Citrate versus heparin anticoagulation for continuous renal replacement therapy: an updated meta-analysis of RCTs.
Intensive Care Med
. 2015 Dec;41(12):2098–110.
© 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.